Haven't lost any weight on Mounjaro? Read this before you give up

The biggest misconception: the first pen should produce instant results

Most people who contact a clinic worried that Mounjaro isn't working are still on 2.5 mg or 5 mg. That is exactly where this misconception bites hardest. The 2.5 mg starting dose exists primarily to let your digestive system adapt, nausea, reflux and stomach discomfort are far less likely if the medicine is introduced gently. At that dose, meaningful appetite suppression for most people is modest at best.

The SURMOUNT-1 trial, which followed around 2,500 adults with obesity over 72 weeks, found average weight reductions of around 20% at the 15 mg maintenance dose. That headline figure is reached after months of titration, not weeks. Expecting the first or second pen to deliver it sets up an unfair comparison. A more useful question than "why haven't I lost weight yet" is: how long have I actually been at a therapeutic dose?

Dose titration is a clinical decision made by your prescriber, typically moving upward every four weeks if you're tolerating the current level. Rushing it can increase side-effect risk; staying too long at a tolerability dose delays results. If you're unsure where you are in that process, our Mounjaro overview walks through how the schedule works in practice.

What the scales are hiding: water, hormones and the first few weeks

Body weight fluctuates by one to three kilograms across a single day from fluid alone. Hormonal changes, a salty meal, a long journey, increased muscle activity, any of these shift the number temporarily. Starting a GLP-1 medicine can also prompt modest fluid shifts in some people. The result is that genuine fat loss can be happening while the scale reads flat or even ticks up slightly.

Cortisol is worth mentioning here. Stress (including the anxiety of watching the scale every morning) elevates cortisol, which promotes fat storage and water retention. There is a real irony in stalling progress by monitoring progress too intensely. Weekly weigh-ins at the same time of day, same clothing, same conditions, give far more useful data than daily checks.

Sleep matters too, and more than most people expect. Poor or short sleep raises ghrelin (a hunger hormone) and blunts the satiety signals that tirzepatide is trying to amplify. If your sleep has been disrupted (shift work, a new baby, a stressful period at work) that can genuinely counteract part of the medicine's effect on appetite.

Diet and activity: what tirzepatide changes, and what it doesn't

Tirzepatide reduces appetite and slows gastric emptying, it does not override calorie absorption entirely. If overall intake remains higher than the body's energy needs, weight loss will be slow or absent regardless of the dose. This sounds obvious, but appetite suppression is not always uniform: some people find certain foods (particularly high-fat or very sweet ones) remain appealing even when hunger for plain food has dropped.

The NHS patient information for tirzepatide notes that the medicine is prescribed alongside a reduced-calorie diet and increased physical activity, not as a standalone intervention. Protein adequacy and fibre intake are particularly worth reviewing; both improve satiety and help preserve muscle mass, which matters for long-term metabolic rate. If you'd like a broader look at how lifestyle factors interact with treatment, our weight-loss guidance page covers this in more detail.

Physical activity doesn't need to be dramatic. Consistent walking has meaningful effects on insulin sensitivity and energy expenditure. Strength-based activity helps protect lean mass during weight loss, which a prescriber or dietitian can advise on specifically for your situation.

When to raise it with your prescriber, and what they'll want to know

If you've been on a therapeutic maintenance dose for three months or more and have seen genuinely no change in weight or measurements, that is worth discussing, and our page on not losing any weight on Mounjaro can help you understand what that conversation with your prescriber might cover. It may be appropriate to review whether the current dose is optimal, whether there are physiological factors at play (thyroid function, for instance), or whether the treatment plan needs adjusting. It is not a reason to stop treatment without clinical input.

Timing matters in a practical sense too. Progress reviews often get delayed after bank holidays or around Christmas, or when someone's routine changes around a busy period. A missed review shouldn't mean a missed conversation, if you have concerns between scheduled check-ins, it's worth contacting your clinical team rather than waiting.

At nume, every repeat order triggers a fresh clinical review by a GPhC-registered prescriber before anything is dispensed. That review is an opportunity to raise questions about progress, not just a box-ticking exercise. If you want a broader sense of what non-response investigations typically involve, this page looks at the clinical reasons in more detail. And if you've been researching costs alongside your progress worries, this guide to accessing Mounjaro through a regulated UK pharmacy sets out what legitimate private treatment involves.

The right move is rarely to stop. It's to ask the right questions of the right people, and if you're wondering why you haven't lost weight on Mounjaro, our dedicated page explores the most common clinical and lifestyle reasons in detail. Check your eligibility with our prescribers if you'd like a clinical conversation about your specific situation.